QRON Stock Overview
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Qrons Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$0.74 |
| 52 Week Low | US$0.16 |
| Beta | 0.79 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -61.36% |
| 3 Year Change | -75.27% |
| 5 Year Change | -84.54% |
| Change since IPO | -81.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| QRON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | -61.4% | -3.7% | 19.3% |
Return vs Industry: QRON underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: QRON underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| QRON volatility | |
|---|---|
| QRON Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QRON has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine QRON's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 3 | Jonah Meer | qrons.com |
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017.
Qrons Inc. Fundamentals Summary
| QRON fundamental statistics | |
|---|---|
| Market cap | US$2.53m |
| Earnings (TTM) | -US$789.35k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs QRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QRON income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$789.35k |
| Earnings | -US$789.35k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -58.9% |
How did QRON perform over the long term?
See historical performance and comparison